Windlas Biotech Limited Market Cap ($210.48 Million)
Market Cap & Net Worth: Windlas Biotech Limited (WINDLAS)
Windlas Biotech Limited market cap. Windlas Biotech Limited (NSE:WINDLAS) has a market capitalization of $210.48 Million (Rs19.46 Billion) as of October 31, 2026. Listed on the NSE stock exchange, this India-based company holds position #16197 globally and #824 in its home market, demonstrating a 4.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Windlas Biotech Limited's stock price Rs923.40 by its total outstanding shares 21077239 (21.08 Million).
Windlas Biotech Limited Market Cap History (2021–2026)
Windlas Biotech Limited market cap history from 2021 to 2026. Data shows growth from $60.96 Million to $210.48 Million (17.74% CAGR). Check Windlas Biotech Limited stock price for real-time trading data and today's change.
Windlas Biotech Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Windlas Biotech Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see WINDLAS cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.02x
Windlas Biotech Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.30x
Windlas Biotech Limited's market cap is 0.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $60.96 Million | $4.27 Billion | $158.32 Million | 0.01x | 0.39x |
| 2022 | $56.07 Million | $4.63 Billion | $380.89 Million | 0.01x | 0.15x |
| 2023 | $97.12 Million | $5.11 Billion | $426.26 Million | 0.02x | 0.23x |
| 2024 | $237.32 Million | $6.29 Billion | $581.87 Million | 0.04x | 0.41x |
| 2025 | $181.23 Million | $7.60 Billion | $609.94 Million | 0.02x | 0.30x |
Competitor Companies of WINDLAS by Market Capitalization
Companies near Windlas Biotech Limited in the global market cap rankings as of October 31, 2026. See Windlas Biotech Limited (WINDLAS) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to Windlas Biotech Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Windlas Biotech Limited (2021–2026)
Market capitalization of Windlas Biotech Limited from 2021 to today. Between 2021 and today, Windlas Biotech Limited's market cap moved from $60.96 Million to $ 210.48 Million, with a yearly change of 17.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs210.48 Million | +16.14% |
| 2025 | Rs181.23 Million | -23.64% |
| 2024 | Rs237.32 Million | +144.35% |
| 2023 | Rs97.12 Million | +73.21% |
| 2022 | Rs56.07 Million | -8.02% |
| 2021 | Rs60.96 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Windlas Biotech Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $210.48 Million USD |
| MoneyControl | $210.48 Million USD |
| MarketWatch | $210.48 Million USD |
| marketcap.company | $210.48 Million USD |
| Reuters | $210.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more